Clinical Trial Search

Primary: Development of Advanced AMD in People at Moderate to High Risk for Progression. — 493; 468; 507; 472 Eyes — p=<0.013

Primary: Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years — 0.315; 0.307; 0.315; 0.320 density units — p=<0.05

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Rate of Change in Area of Geographic Atrophy (GA), Based on Masked, Digital Grading of Fundus Photography by an External Reading Center, in the Study Eye at 12 Months…

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye — 23.7; 25.7; 27.6; 41.5 letters

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: LL BCVA Score Change From Baseline — 0.7; -0.6; 1.1; -0.8 Letters

Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: Difference in Square-Root Transformed GA Area Expansion Rates in the Study Eye Between the Treatment Phase and Run-in Phase Based on Fundus Autofluorescence (FAF)…

Primary: Targeted Vision Function (TVF) — 2.18; 2.14 units on a scale — p=.47

Primary: Incidence and Severity of Ocular Adverse Events (AEs) — 1; 3; 2; 1 participants

Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters

Primary: Monthly Rates of Anti-VEGF (Vascular Endothelial Growth Factor) Injections — 0.42; 0.83; 0.34; 0.83 Injections per Month

Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy — 0.41; 0.35 mm/year — p=0.39

Primary: Summary of Adverse Events — 57; 16; 47; 4 participants

Primary: Highest Tolerated Dose (HTD) of AGN-150998 — 4.2 mg

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR…

Primary: Change in Skin Carotenoid Status in Response to Genetic Risk Disclosure as Measured by Reflectance Spectroscopy — 257.7; 290.9 Reflection units (RU)

Primary: Age in Study Participants — 70.6; 77.8 years

Primary: Macular Pigment Optical Density — 0.48; 0.38; 0.42 Density units of Macular Pigment (du)

Primary: Phase I: Percentage of Participants With Adverse Events — 11; 10; 10 Participants — p=1.00

Primary: Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at Week 24 From Baseline — -98; -66; -180.8 Microns

Primary: Number of Participants With Systemic Drug-related Adverse Events — 3; 0 participants

Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters